Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin.
Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin.
复制标题
DOI：
10.1021/mp900138a
复制
发表时间：
2010-02-01
影响因子：
4.9
通讯作者：
Saltzman WM
中科院分区：
文献类型：
--
作者：
Cartiera MS;Ferreira EC;Caputo C;Egan ME;Caplan MJ;Saltzman WM
囊性纤维化（CF）是一种常见的危及生命的遗传性疾病（发病率：约1 / 2500活产）。CF是由CFTR突变引起的，CFTR是一种氯离子通道，参与液体和电解质的上皮分泌。最常见的突变包括508位苯丙氨酸的缺失，导致蛋白质错误折叠和CFTR加工异常。ΔF508突变约占所有CF等位基因的70%，约90%的CF患者携带至少一个ΔF508 CFTR拷贝。姜黄素是姜黄香料的天然成分，是一种无毒的低亲和力SERCA （Sarco （Endo）质网钙atp酶）泵抑制剂，被认为允许ΔF508 CFTR从内质网逃逸。该化合物已被证明能够纠正表达ΔF508 CFTR的细胞系和小鼠的缺陷。在这项工作中，合成了包封姜黄素的聚乳酸-羟基乙酸（PLGA）纳米颗粒，并将其用于治疗两种不同的CF小鼠品系，通过提高化合物的生物利用度来纠正与CF相关的缺陷，这在以前的姜黄素治疗中一直是一个挑战。我们的研究结果表明，与未包封的姜黄素相比，口服包封姜黄素的PLGA纳米颗粒可增强CF小鼠的姜黄素治疗效果。
Cystic fibrosis (CF) is a common life threatening genetic disease (incidence: ~1 in 2500 live births). CF is caused by mutations in CFTR, a chloride channel involved in epithelial secretion of fluid and electrolytes. The most common mutation entails the deletion of a phenylalanine in position 508 that causes protein misfolding and abnormal CFTR processing. The ΔF508 mutation accounts for approximately 70% of all CF alleles and about 90% of CF patients carry at least one copy of ΔF508 CFTR. Curcumin, a natural constituent of Curcuma Longa (turmeric spice), is a non-toxic low-affinity SERCA (Sarco (Endo)plasmic Reticulum Calcium ATPase) pump inhibitor thought to permit ΔF508 CFTR escape from the ER. The compound has been shown to be capable of correcting the defect in cell lines and mice expressing ΔF508 CFTR. In this work, poly-lactic-co-glycolic acid (PLGA) nanoparticles encapsulating curcumin were synthesized and used to treat two different CF mouse strains in an effort to correct the defects associated with CF by improving bioavailability of the compound, which has previously been a challenge in treatment with curcumin. Our results suggest that oral administration of PLGA nanoparticles encapsulating curcumin enhances the effects of curcumin therapy in CF mice, as compared to delivery of non-encapsulated curcumin.
登录
查看更多内容
影响因子：
56.9
作者：
Egan, ME;Pearson, M;Caplan, MJ
通讯作者：
Caplan, MJ
影响因子：
--
作者：
Lao, Christopher D;Ruffin, Mack T 4th;Brenner, Dean E
通讯作者：
Brenner, Dean E
影响因子：
10.2
作者：
Bisht S;Feldmann G;Soni S;Ravi R;Karikar C;Maitra A;Maitra A
通讯作者：
Maitra A
DOI：
10.1016/j.bbrc.2004.10.070
发表时间：
2004-12-10
影响因子：
3.1
作者：
Loo, TW;Bartlett, MC;Clarke, DM
通讯作者：
Clarke, DM
DOI：
10.1046/j.0014-2956.2001.02589.x
发表时间：
2001-12-01
期刊：
EUROPEAN JOURNAL OF BIOCHEMISTRY
影响因子：
--
作者：
Bilmen, JG;Khan, SZ;Michelangeli, F
通讯作者：
Michelangeli, F